JNJ

Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Endpoints
Samsung Bioepis
Remicade
FDA
biosimilars
JNJ
GSK
Benlysta
lupus
Flag link:
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
Fierce Pharma
JNJ
Remicade
biosimilars
Pfizer
Inflectra
Flag link:
Johnson & Johnson CEO Gorsky: Verb Surgical robotics program ‘on track’
Johnson & Johnson CEO Gorsky: Verb Surgical robotics program ‘on track’
Mass Device
JNJ
Pharma CEOs
Alex Gorsky
Verb Surgical
surgical robots
devices
Flag link:
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
Fierce Pharma
JNJ
Invokana
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
Flag link:
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Motley Fool
JNJ
earnings
Flag link:
5 Big Pharma Stocks With the Best Drug Pipelines
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Big Pharma
Roche
AstraZeneca
AbbVie
Gilead Sciences
JNJ
Flag link:
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
Motley Fool
JNJ
earnings
Flag link:
Johnson & Johnson’s 2Q17 Estimates: Medical Devices
Johnson & Johnson’s 2Q17 Estimates: Medical Devices
Market Realist
JNJ
earnings
devices
Ethicon
Animas
LifeScan
Biosense Webster
DePuy Synthes
Mentor
Flag link:
J&J's Tremfya approved, further crowding IL-inhibitor market
J&J's Tremfya approved, further crowding IL-inhibitor market
BioPharma Dive
JNJ
Tremfya
psoriasis
Interleukin-inhibitors
guselkumab
Flag link:
The top 15 highest-paid biopharma executives
The top 15 highest-paid biopharma executives
Fierce Pharma
executive pay
Mylan Labs
Valeant Pharmaceuticals
Medivation
Regeneron
JNJ
Merck
Flag link:
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
J&J gets a quick FDA OK for its blockbuster psoriasis contender guselkumab
J&J gets a quick FDA OK for its blockbuster psoriasis contender guselkumab
Endpoints
JNJ
FDA
psoriasis
guselkumab
Flag link:
Johnson & Johnson earnings: A challenging second quarter poised for a turnaround
Johnson & Johnson earnings: A challenging second quarter poised for a turnaround
Marketwatch
JNJ
earnings
Flag link:
[video]How Portola Is Looking to Change the Anticoagulant Game
[video]How Portola Is Looking to Change the Anticoagulant Game
Motley Fool
Portola Pharmaceuticals
anticoagulants
Bevyxxa
JNJ
Pfizer
Flag link:
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
Motley Fool
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
AbbVie
JNJ
Imbruvica
Pfizer
Ibrance
cancer
Flag link:
Medtech Mergers Surge Again
Medtech Mergers Surge Again
Seeking Alpha
devices
M&A
Abbott Labs
Cutera
St. Jude Medical
Allergan
Syneron
JNJ
Flag link:
Will Johnson & Johnson's Dividend Keep Climbing?
Will Johnson & Johnson's Dividend Keep Climbing?
Motley Fool
JNJ
dividends
Flag link:
J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it
J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it
Endpoints
JNJ
Capricor
stem cells
Linda Marban
Flag link:
Inside JNJ’s Inorganic Strategy in Medical Devices: The Latest Acquisitions
Inside JNJ’s Inorganic Strategy in Medical Devices: The Latest Acquisitions
Market Realist
JNJ
devices
M&A
Sentio
Abbott Medical Optics
Neuravi
Flag link: